Effectiveness of long-term hormone therapy for endometriosis after surgical treatment


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the effectiveness of long-term dydrogesterone therapy for 12 months after surgical treatment of external genital endometriosis in reducing the intensity of endometriosis-associated pain, improving the quality of life, overcoming infertility and preventing the recurrence of the disease. Materials and methods. The study included 51 patients aged 21 to 43 years (median age 32.23+4.0 years) with endometriosis which was confirmed laparoscopically and histologically; the patients experienced endometriosis-associated pain and received hormone-modulating therapy with dydrogesterone in the postoperative period. After 12 months of combined treatment, the dynamics of pain relief, improvement in the quality of life, and pregnancy rate in infertile women were evaluated. Histological and immunohistochemical studies were used to determine the characteristics of endometrioid infiltrates and intact peritoneum in patients with pelvic pain of varying intensity. Results. After 12 months of combined treatment of endometriosis (surgical and dydrogesterone therapy), there was a statistically significant decrease in pain intensity (NRS, points): the intensity of dysmenorrhea before surgery was rated as 8 (6;9), after surgery it scored 1 (0;2), the intensity of dyspareunia - 5 (2;7) and 0 (0;0.5), chronic pelvic pain - 6 (1;6) and 1 (0;2), respectively (p<0.0001). There was a statistically significant improvement in the quality of life and satisfaction with sexual life (p<0.05), as well as high pregnancy rate in patients with infertility: 10 (62%) patients became pregnant spontaneously, and 3 (19%) patients became pregnant using ART. Conclusion. The study proves the need for combined surgical and prolonged hormonal treatment of endometriosis; long-term dydrogesterone therapy for 12 months appears to be highly effective in the treatment of endometriosis-associated pain, infertility, and prevention of the recurrence of the disease. Dydrogesterone has a favorable safety profile and allows doctors to personalize the treatment of endometriosis depending on the current needs of patients.

Full Text

Restricted Access

About the authors

Vitaly F. Bezhenar

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: bez-vitaly@yandex.ru
Dr. Med. Sci., professor, Head of the Departments of Obstetrics, Gynecology and Neonatology/Obstetrics, Gynecology and Reproductology

Sergey Yu. Kruglov

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: skruglov89@mai.ru
PhD, Assistant of the Department of Obstetrics, Gynecology and Reproductology

Natalya S. Kuzmina

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: dok.kuzmina@gmail.com
PhD, Assistant of the Department of Obstetrics, Gynecology and Neonatology, Head of the Department of Oncology No. 7 (Oncogynecology) of the Clinic of Obstetrics and Gynecology

Yulia S. Krylova

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

PhD, Assistant of the Department of Pathological Anatomy with the Pathological Department

Alina S. Sergienko

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: md.sergienko@gmail.com
postgraduate student of the Department of Obstetrics, Gynecology and Reproductology

Ainur K. Abilbekova

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: ainur.abilbekova@yahoo.com
postgraduate student of the Department of Obstetrics, Gynecology and Reproductology

Tatyana Yu. Zhemchuzhina

I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia

Email: tzhemchuzhina@mail.ru
PhD, Associate Professor of the Department of Obstetrics, Gynecology and Reproductology

References

  1. Vercellini P., Buggio L, Frattaruolo M.P., Borghi A., Dridi M., Somigliana E. Medical treatment of endometriosis-related pain. Best Pract. Res. Clin. Obstet. Gynecol. 2018; 51: 68-91. https://dx.doi.org/10.1016/ j.bpobgyn.2018.01.015.
  2. БеженарьВ.Ф., КругловС.Ю., АракелянБ.В.,КузьминаН.С.,Паластин П.М., Крылова Ю.С. Нервсберегающие операции при глубоком инфильтративном эндометриозе. Доктор.Ру. 2019; 7: 40-5. https://dx.doi.org/10.31550/1727-2378-2019-162-7-40-45.
  3. Dunselman G.A.J., Vermeulen N., Becker C., Calhaz-JKorge C., DHooghe T., De Bie B. et al. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014; 29(3): 400-12. https://dx.doi.org/10.1093/humrep/ det457.
  4. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. М.; 2016. ID: КР259. Available at: http:// cr.rosminzdrav.ru/#!/recomend/182 [Endometriosis. Clinical guidelines. 2016. ID: KR259. Access from the website of the Ministry of Health of the Russian Federation: http://cr.rosminzdrav.ru/#!/recomend/182 (checked 28.03.2018) (in Russian)].
  5. Дубровина С.О., Беженарь В.Ф., ред. Эндометриоз. Патогенез, диагностика, лечение. М.: ГЭОТАР-Медиа; 2020. 352 с. [Dubrovina S.O., Bezhenar V.F., eds. Endometriosis, Pathogenesis, diagnosis, treatment. Moscow: GEOTAR-Media, 2020. 352 p. (in Russian)].
  6. Trivedi P., Selvaraj K., Mahapatra P.D., Srivastava S., Malik S. Effective post-laparoscopic treatment of endometriosis with dydrogesterone. Gynecol. Endocrinol. 2007; 23(Suppl. 1): 73-6. https://dx.doi. org/10.1080/09513590701669583.
  7. Дубровина С.О., Берлим Ю.Д. Гестагены в терапии эндометрио за. Акушерство и гинекология. 2018; 5: 150-5. [Dubrovina S.O., Berlim Yu.D. Gestagens in the therapy of endometriosis. Obstetrics and gynecology. 2018; 5: 150-5. (in Russian)]. https://dx.doi.org/10.18565/ aig.2018.5.150-155.
  8. Сухих Г.Т., Адамян Л.В., Козаченко А.В., Дубровина С.О., Баранов И.И., Радзинский В.Е. и др. Дидрогестерон для лечения подтвержденного эндометриоза: ключевые результаты наблюдательного открытого многоцентрового исследования в условиях реальной клинической практики (исследование ОРХИДЕЯ). Акушерство и гинекология: новости, мнения, обучение. 2020; 8(4): 79-81. [Sukhikh G.T., Adamyan L.V., Kozachenko A.V., Dubrovina S.O., Baranov I.I., Radzinsky V.E. et al. Dydrogesterone for the treatment of confirmed endometriosis: key results of an observational open multicenter study in real clinical practice (ORCHIDEA study). Obstetrics and gynecology: news, opinions, training. 2020; 8(4): 79-81. (in Russian)]. https:// dx.doi.org/10.24411/2303-9698-2020-14006.
  9. Подзолкова Н.М., Татарчук Т.Ф., Дощанова А.М., Ешимбетова Г.З., Сумятина Л.В. Нормализация менструального цикла дидрогестероном. Акушерство и гинекология. 2018; 6: 70-6. [Podzolkova N.M., Tatarchuk T.F., Doschanova A.M., Eshimbetova G.Z., Sumyatina L.V. Dydrogesterone treatment for menstrual-cycle regularization. Obstetrics and gynecology. 2018; 6: 70-6 (in Russian)]. https://dx.doi.org/10.18565/ aig.2018.6.70-76.
  10. Tournaye H., Sukhikh G.T., Kahler E., Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum. Reprod. 2017; 32(5): 1019-27. https://dx.doi. org/10.1093/humrep/dex023.
  11. Backer M.H. Jr. Isopregnenone (Duphaston): a new progestational agent. Obstet. Gynecol, 1962; 19: 724-9.
  12. Johnston W.I.H. Dydrogesterone and endometriosis. BJOG. 1976; 83: 77-80.
  13. Kaiser E., Wagner Th.A. Die Behandlung der Endometriose mit Dydrogesteron. TW Gynakologie. 1989; 2: 386-8.
  14. Makhmudova G.M., Gafarova D.Kh., Nazhmutdinova D.K., Lukmanova L.D. Efficacy of duphaston treatment in women with endometriosis after reconstructive surgery. Akush. Ginekol. (Sofiia). 2003; 42(4): 42-6.
  15. Pandian R.U. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009; 65(Suppl. 1): S47
  16. -50. https://dx.doi.org/10.1016/j.maturitas.2009.11.016.
  17. Trivedi N., Chauhan N., Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol. Endocrinol. 2016: 32(8): 667-71. https://dx.doi.org/10.3109/09513590.2016.1152238.
  18. Taniguchi F., Ota I., Iba Y., Toda T., Tagashira Y., Ohata Y. et al. The efficacy and safety of dydrogesterone for treatment of dysmenorrhea: An open-label multicenter clinical study. J. Obstet. Gynaecol. Res. 2019; 45(1): 168-75. https://dx.doi.org/10.1111/jog.13807.
  19. Balasch J., Vanrell J., Marquez M., Gonzalez-Merlo J. Dehydrogesterone treatment of endometrial luteal phase deficiency after ovulation induced by clomiphene citrate and human chorionic gonadotropin. Fertil. Steril. 1983; 40(4): 469-71. https://dx.doi.org/10.1016/ s0015-0282(16)47356-5.
  20. Савельева Г.М., Сухих Г.Т., Серов В.Н., Манухин И.Б., Радзинский В.Е., ред. Гинекология. Национальное руководство. 2-е изд. М.: ГЭОТАР-Медиа; 2017. 1048 с. [Savelyeva G.M., Sukhikh G.T., Serov V.N., Manukhin I.B., Radzinsky V.E., ed. Gynecology. National guideline. 2nd ed. Moscow: GEOTAR-Media, 2017. 1048 p. (in Russian)].
  21. Schweppe K.W. The place of dydrogesterone in the treatment of endometriosis and adenomyosis. Maturitas. 2009; 65(Suppl. 1): S23-7. https://dx.doi. org/10.1016/j.maturitas.2009.11.011.
  22. Инструкция по медицинскому применению препарата Дюфастон® Ссыллка активна на: 06.07.2020. [Instruction on the medical use of the drug Dufaston® Accessed 06.07.2020. (in Russian)].
  23. Ryder T., Mobberley M., Whitehead M. The endometrial nucleolar channel system as an indicator of progestin potency in HRT. Maturitas. 1995; 22(1): 31-6. https://dx.doi.org/10.1016/0378-5122(95)00912-5.
  24. Pallacks C., Hirchenhain J., Krussel J.S., Fehm T.N., Fehr D. Endometriosis doubles odds for miscarriage in patients undergoing IVF or ICSI. Eur. J. Obstet. Gynecol. Reprod. Biol. 2017; 213: 33-8. https://dx.doi.org/10.1016/j. ejogrb.2017.04.008.
  25. Santulli P., Marcellin L., Menard S., Thubert T., Khoshnood B., Gayet V. et al. Increased rate of spontaneous miscarriages in endometriosis-affected women. Hum. Reprod. 2016; 31(5): 1014-23. https://dx.doi.org/10.1093/humrep/ dew035.
  26. Nickkho-Amiry M., Savant R., Majumder K., Edi-O’sagie E., Akhtar M. The effect of surgical management of endometrioma on the IVF/ ICSI outcomes when compared with no treatment? A systematic review and meta-analysis. Arch. Gynecol. Obstet. 2018; 297(4): 1043-57. https://dx.doi.org/10.1007/ s00404-017-4640-1.
  27. Carp H.J.A. Progestogens and pregnancy loss. Climacteric. 2018; 21(4): 380-4. https://dx.doi.org/10.1080/13697137.2018.1436166.
  28. Guideline of the European Society of Human Reproduction and Embryology (ESHRE). Recurrent pregnancy loss. Available at: https://www.eshre.eu/ Guidelines-and-Legal/Guidelines/Recurrent-pregnancy loss.aspx Accessed June 11, 2018.
  29. Toth B., Wurfel W., Bohlmann M., Zschocke J., Rudnik-Schoneborn S., Nawroth F. et al. Recurrent miscarriage: diagnostic and therapeutic procedures. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry Number 015/050). Geburtshilfe Frauenheilkd. 2018; 78(4): 364-81. https://dx.doi.org/10.1055/a-0586-4568.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies